Nicholas Jacobus is a content associate for Pharmaceutical Executive and can be reached at njacobus@mjhlifesciences.com.
In today’s Pharmaceutical Executive Daily, the FDA issues a refusal-to-file letter to Moderna for its seasonal influenza vaccine as the company secures a long-term agreement in Mexico, industry leaders assess China’s evolving role in global pharma strategy, and the FDA makes a decision on Keytruda in platinum-resistant ovarian cancer.
THX Pharma’s licensing deal with Biocodex pairs late-stage rare disease assets with commercial infrastructure and non-dilutive funding, highlighting how biotech companies are sharing risk and leveraging partnerships to advance ultra-rare pediatric programs toward market.
A regulatory setback for Moderna’s next-generation flu vaccine underscores mounting scrutiny of late-stage trial design in the U.S., even as the company pivots to international manufacturing partnerships to sustain momentum in its respiratory franchise.
Yerem Yeghiazarians founder, CEO of Soley Therapeutics, talks about how drug discovery is a team effort, noting that success requires a strong vision, hands-on leadership, and a talented staff.
Kim Boericke, CEO, Veristat, notes that advancing women into STEM leadership requires strong advocacy from senior leaders, strategic career planning, and building visibility through cross-functional collaboration and networking.
In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum Technologies close Series B financing rounds, and Iambi enters a $1 billion collaboration with Takeda to advance small-molecule programs.
QuantX Biosciences and Pandorum Technologies have closed new Series B financing rounds, raising $85 million and $18 million respectively, to advance their platform-driven approaches.
The collaboration will employ Iambi’s AI drug discovery technology to advance several small molecule programs in oncology, gastrointestinal, and inflammatory diseases.
Yerem Yeghiazarians founder, CEO of Soley Therapeutics, discusses how Soley uses human cells to guide drug discovery, improving translation to patients and transforming how new therapeutics are developed.
In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate real-world data, and Eli Lilly enters an $8 billion strategic collaboration involving Innovent and Orna Therapeutics.
Hims & Hers moved to remove access to its compounded semaglutide offering following mounting regulatory scrutiny and legal pressure from Novo Nordisk.
Eli Lilly’s deals with Orna Therapeutics and Innovent Biologics helps structure Lilly's global development and commercialization in ways that balance regional expertise with worldwide scale.
Yerem Yeghiazarians founder and CEO of Soley Therapetuics touches on how Soley's approach reverses traditional drug development and reduces failure risks.
In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerges as a force multiplier for small and mid-size biotech companies.
Novo Nordisk is using its first Super Bowl commercial to spotlight an oral formulation of Wegovy that builds on prior approvals of semaglutide, signaling a strategy to expand obesity treatment access beyond injectable GLP-1s.
FDA Commissioner Marty Makary’s warning against mass-marketed copycat drugs escalated the regulatory and legal clash over compounded oral GLP-1 products.
In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical protocols should be treated as product launch blueprints, and Veradermics completes an upsized $256 million IPO.
The approval is for a new formulation of the medication that allows for it be provided as an oral film.
Veradermics’ above-range IPO highlights renewed investor selectivity in biotech, favoring late-stage companies with clear clinical milestones and exposure to large, consumer-driven markets.
In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders explore how pharma can tap into emerging talent hubs, and Novartis’ Q4 results highlight mounting pressure from its upcoming patent cliff.
Novo Nordisk posted strong 2025 sales growth driven by obesity treatments and U.S. market performance, but tempered operating profits signal a more cautious outlook for 2026.
Novartis reported solid full-year growth and margin expansion in 2025, but also set the stage for a challenging year ahead marked by major patent expirations.
The outlook highlights major progress in reducing U.S. breast cancer deaths through improved screening and treatment, while noting that rising incidence and ongoing disparities continue to challenge patients and the health care system.
In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous indication of Saphnelo, and SanegeneBio enters a $1 billion global licensing agreement with Genentech focused on RNAi development.
Dave Carey, CEO, Preceptis Medical and Michael Monovoukas, CEO, co-founder, AcuityMD note the importance of shifting ear tube procedures into the office, reducing anesthesia risk, and how AI-driven data and adaptive commercial strategies are becoming critical to scaling new medtech innovations.
FDA’s complete response letter for subcutaneous Saphnelo highlights regulatory scrutiny around manufacturing and formulation changes in the industry.
The deal highlights how RNAi is moving into a more industrial phase of drug development, as large pharmaceutical companies look to pair advanced delivery technologies with the scale and durability
In today’s Pharmaceutical Executive Daily, the FDA introduces a PreCheck pilot program aimed at strengthening domestic manufacturing oversight, an ACIP member alleges FDA leadership halted a decision related to COVID-19 vaccines, and Eli Lilly announces plans for a $3 billion manufacturing facility in Pennsylvania.
A public clash is emerging between ACIP advisers and the FDA over the future of Covid vaccines, as ACIP vice chair Robert Malone publicly accuses Commissioner Marty Makary of blocking efforts to remove the shots from the market.
The facility builds on Eli Lilly's $50 Billion investment strategy to strengthen the company's domestic manufacturing capabilities.
